Cogent Biosciences
COGT
44 hedge funds and large institutions have $221M invested in Cogent Biosciences in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
57% more funds holding
Funds holding: 28 → 44 (+16)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
19% more capital invested
Capital invested by funds: $186M → $221M (+$35M)
3.8% more ownership
Funds ownership: 47.74% → 51.54% (+3.8%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
+$15M |
| 2 |
CI
Cowen Inc
New York
|
+$6.98M |
| 3 |
BlackRock
New York
|
+$5.36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.16M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$2.78M |
| 3 |
Morgan Stanley
New York
|
-$2.26M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.09M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.94M |
COGT Hedge Fund Activity: Q2 2018 in Review
44 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2018, worth a combined $221M — up 19% from $186M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new COGT positions and 11 closed out — a net gain of 17 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was New Leaf Venture Partners, adding an estimated $15M. The largest seller was Sabby Management, cutting an estimated $3.16M.
- 44 institutional investors held Cogent Biosciences (COGT) as of Q2 2018, up from 28 in Q1 2018.
- Funds reported $221M of Cogent Biosciences stock for Q2 2018, up 19% quarter-over-quarter.
- 28 funds opened new Cogent Biosciences positions in Q2 2018 and 11 closed out, a net change of +17 holders.
- The largest Cogent Biosciences buyer in Q2 2018 was New Leaf Venture Partners, an estimated $15M added.
- The largest Cogent Biosciences seller in Q2 2018 was Sabby Management, an estimated $3.16M sold.
Based on aggregated 13F filings for Q2 2018.